View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Feb. 15 (HealthDay News) -- New data on birth outcomes provide some reassurance to women who are inadvertently exposed to leflunomide before or during pregnancy, according to research published online Feb. 3 in Arthritis & Rheumatism.
To examine birth outcomes, Matteo Cassina, M.D., of the University of Padua in Italy, and colleagues collected data from 16 women exposed to leflunomide during the first trimester, and 29 women exposed prior to conception, who contacted Teratology Information Services in the United States or Canada.
The researchers found that 27 (93 percent) of the women who were exposed to leflunomide prior to conception, and all 16 of the women exposed to leflunomide during their first trimester, had live born infants. In the women exposed during pregnancy, there were two infants with major malformations, but no malformations occurred in women exposed prior to conception. Potential alternative causes of the malformations were available for at least some of defects observed.
"These data provide additional reassurance to women who inadvertently become pregnant while taking leflunomide and who undergo the washout procedure, and women who discontinue the medication prior to conception but have no pre-pregnancy documentation of drug clearance. However, until more conclusive data become available, women on therapy should be advised to use contraceptive methods and avoid pregnancy," the authors write.
The study was funded by Sanofi-Aventis, which manufactures leflunomide.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top